{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:16:59Z","timestamp":1772990219317,"version":"3.50.1"},"reference-count":61,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024872","name":"Toegepaste en Technische Wetenschappen, NWO","doi-asserted-by":"publisher","award":["17915"],"award-info":[{"award-number":["17915"]}],"id":[{"id":"10.13039\/501100024872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["17915"],"award-info":[{"award-number":["17915"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>PSA is the most common biomarker used in the screening and monitoring of prostate cancer. However, changes in PSA do not always reflect disease dynamics in every patient, and antihormonal agents may modulate its levels without significant antitumor effects. Changes in circulating tumor cells (CTC) have been described as a more objective measure of treatment response. Differences between PSA and CTC may be explained by heterogeneity in tumor cells producing PSA. To explore this, we measured the PSA secretion from a single CTC to gain insights into the PSA secretion heterogeneity between tumor cells. CTCs were enriched using EpCAM-based immunomagnetic enrichment in diagnostic leukapheresis of 18 patients with metastatic castration-na\u00efve prostate cancer (mCNPC) not pretreated with any therapy, including androgen deprivation therapy. Calcein+ CD45\u2212 cells were sorted by flow cytometry and deposited as single cells on a nanowell array to measure the PSA secretion after 24 hours. In nine of 18 patients, PSA secretion was detectable and observed from both prostate-specific membrane antigen\u2013positive and prostate-specific membrane antigen\u2013negative CTCs. In these patients, 29% to 100% (mean, 52; median, 47) of CTCs secreted PSA, with average PSA secretion levels ranging from 4 to 11.68 pg\/cell (mean, 6.38 \u00b1 2.29; median, 6.05). Notably, a strong heterogeneity in PSA secretion was observed within each patient. Our study demonstrates that CTC in mCNPC, even before therapy, produces varying amounts of PSA and often no PSA. These findings may explain the shortcomings of PSA as a biomarker for therapy response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study reveals heterogeneity in PSA secretion among individual CTCs from patients with mCNPC prior to any therapeutic intervention, thereby highlighting the limitations of PSA as a biomarker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0158","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T11:36:49Z","timestamp":1753961809000},"page":"1359-1371","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Na\u00efve Prostate Cancer Patients"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9389-029X","authenticated-orcid":false,"given":"Eshwari","family":"Dathathri","sequence":"first","affiliation":[{"name":"1Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8970-1206","authenticated-orcid":false,"given":"Fikri","family":"Abali","sequence":"additional","affiliation":[{"name":"1Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8643-7235","authenticated-orcid":false,"given":"Michiel","family":"Stevens","sequence":"additional","affiliation":[{"name":"1Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands."},{"name":"2VYCAP, Enschede, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2270-1284","authenticated-orcid":false,"given":"Richell","family":"Booijink","sequence":"additional","affiliation":[{"name":"1Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2594-2227","authenticated-orcid":false,"given":"Tanja C.","family":"van Dijk","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-5206","authenticated-orcid":false,"given":"Khrystany T.","family":"Isebia","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3428-3366","authenticated-orcid":false,"given":"John W.M.","family":"Martens","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7445-7984","authenticated-orcid":false,"given":"Jaco","family":"Kraan","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5462-9486","authenticated-orcid":false,"given":"Nick","family":"Beije","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0466-2928","authenticated-orcid":false,"given":"Martijn P.","family":"Lolkema","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."},{"name":"4Amgen, Thousand Oaks, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3566-5016","authenticated-orcid":false,"given":"Peter A.W.","family":"te Boekhorst","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8223-0250","authenticated-orcid":false,"given":"Paul","family":"Hamberg","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam\/Schiedam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6869-7264","authenticated-orcid":false,"given":"Brigitte C.M.","family":"Haberkorn","sequence":"additional","affiliation":[{"name":"7Department of Medical Oncology, Maasstad Hospital, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8792-0368","authenticated-orcid":false,"given":"Danny","family":"Houtsma","sequence":"additional","affiliation":[{"name":"8Department of Internal Medicine, Haga Hospital, The Hague, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8236-4148","authenticated-orcid":false,"given":"Joan","family":"van den Bosch","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2629-2245","authenticated-orcid":false,"given":"Wendy M.","family":"van der Deure","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology, Groene Hart Hospital, Gouda, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2470-5876","authenticated-orcid":false,"given":"Ruchi","family":"Bansal","sequence":"additional","affiliation":[{"name":"1Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5944-3787","authenticated-orcid":false,"given":"Leon W.M.M.","family":"Terstappen","sequence":"additional","affiliation":[{"name":"1Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands."},{"name":"11Department of General, Visceral and Pediatric Surgery, Heinrich-Heine University, University Hospital D\u00fcsseldorf, D\u00fcsseldorf, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"2025081803480053200_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2025081803480053200_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2025081803480053200_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025081803480053200_bib4","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025081803480053200_bib5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2025081803480053200_bib6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"2025081803480053200_bib7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"2025081803480053200_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","article-title":"Deep and durable prostate-specific antigen response to Darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: analyses of the randomized phase 3 ARASENS study","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"key":"2025081803480053200_bib9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","article-title":"Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"issue":"Suppl 16","key":"2025081803480053200_bib10","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1200\/JCO.2022.40.16_suppl.5072","article-title":"Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of ARCHES","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025081803480053200_bib11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.euo.2020.07.001","article-title":"Patterns of cancer progression of metastatic hormone-sensitive prostate cancer in the ECOG3805 CHAARTED trial","volume":"3","author":"Bryce","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"2025081803480053200_bib12","doi-asserted-by":"crossref","first-page":"863472","DOI":"10.3389\/fonc.2022.863472","article-title":"Liquid biopsy based circulating biomarkers in metastatic prostate cancer","volume":"12","author":"Dathathri","year":"2022","journal-title":"Front Oncol"},{"key":"2025081803480053200_bib13","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3390\/cancers16061213","article-title":"Advancements in circulating tumor cell research: bridging biology and clinical applications","volume":"16","author":"Salu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025081803480053200_bib14","first-page":"237","article-title":"Clinical application of circulating tumor cells","volume":"35","author":"Stoecklein","year":"2023","journal-title":"Med Genet"},{"key":"2025081803480053200_bib15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2013.51.7417","article-title":"Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer","volume":"32","author":"Goldkorn","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025081803480053200_bib16","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer","volume":"33","author":"Scher","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025081803480053200_bib17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2017.75.2998","article-title":"Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials","volume":"36","author":"Heller","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025081803480053200_bib18","doi-asserted-by":"crossref","first-page":"48625","DOI":"10.18632\/oncotarget.8015","article-title":"Evaluation and consequences of heterogeneity in the circulating tumor cell compartment","volume":"7","author":"Brouwer","year":"2016","journal-title":"Oncotarget"},{"key":"2025081803480053200_bib19","doi-asserted-by":"crossref","first-page":"111314","DOI":"10.1016\/j.biopha.2021.111314","article-title":"Heterogeneity of CTC contributes to the organotropism of breast cancer","volume":"137","author":"Yu","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2025081803480053200_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2021.03.023","article-title":"Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells","volume":"150","author":"Mout","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025081803480053200_bib21","doi-asserted-by":"crossref","first-page":"e0226219","DOI":"10.1371\/journal.pone.0226219","article-title":"Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer","volume":"15","author":"Nagaya","year":"2020","journal-title":"PLoS One"},{"key":"2025081803480053200_bib22","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-22-3233","article-title":"PSMA-Positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate-resistant prostate cancer","volume":"29","author":"Gupta","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025081803480053200_bib23","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.3390\/cancers13236083","article-title":"Measurement of the drug sensitivity of single prostate cancer cells","volume":"13","author":"Abali","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025081803480053200_bib24","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1373\/clinchem.2005.049445","article-title":"Detection of circulating prostate-specific antigen\u2013secreting cells in prostate cancer patients","volume":"51","author":"Alix-Panabi\u00e8res","year":"2005","journal-title":"Clin Chem"},{"key":"2025081803480053200_bib25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3390\/cancers17050721","article-title":"Secretome analysis of prostate cancer cell lines reveals cell cycle-dependent PSA secretion and potential biomarkers","volume":"17","author":"Dathathri","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2025081803480053200_bib26","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1038\/s41598-024-60054-1","article-title":"A nanowell platform to identify, sort and expand high antibody-producing cells","volume":"14","author":"Abali","year":"2024","journal-title":"Sci Rep"},{"key":"2025081803480053200_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nprot.2016.006","article-title":"Organoid culture systems for prostate epithelial and cancer tissue","volume":"11","author":"Drost","year":"2016","journal-title":"Nat Protoc"},{"key":"2025081803480053200_bib28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/cyto.a.24779","article-title":"Improved enrichment of circulating tumor cells from diagnostic leukapheresis product","volume":"103","author":"Stevens","year":"2023","journal-title":"Cytometry A"},{"key":"2025081803480053200_bib29","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1039\/C9LC00100J","article-title":"A microwell array platform to print and measure biomolecules produced by single cells","volume":"19","author":"Abali","year":"2019","journal-title":"Lab Chip"},{"key":"2025081803480053200_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/ijms20030477","article-title":"Self-seeding microwells to isolate and assess the viability of single circulating tumor cells","volume":"20","author":"Andree","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025081803480053200_bib31","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1210\/mend-5-12-1921","article-title":"The promoter of the prostate-specific antigen gene contains a functional androgen responsive element","volume":"5","author":"Riegman","year":"1991","journal-title":"Mol Endocrinol"},{"key":"2025081803480053200_bib32","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1074\/jbc.271.11.6379","article-title":"Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter","volume":"271","author":"Cleutjens","year":"1996","journal-title":"J Biol Chem"},{"key":"2025081803480053200_bib33","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-0746-3","article-title":"Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications","volume":"10","author":"Rahman","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2025081803480053200_bib34","doi-asserted-by":"crossref","first-page":"36865","DOI":"10.1074\/jbc.R100041200","article-title":"Coregulator codes of transcriptional regulation by nuclear receptors","volume":"276","author":"Rosenfeld","year":"2001","journal-title":"J Biol Chem"},{"key":"2025081803480053200_bib35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/jcb.20228","article-title":"Prostate specific antigen gene regulation by androgen receptor","volume":"93","author":"Kim","year":"2004","journal-title":"J Cell Biochem"},{"key":"2025081803480053200_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1015531326689","article-title":"Contribution of the androgen receptor to prostate cancer predisposition and progression","volume":"20","author":"Buchanan","year":"2001","journal-title":"Cancer Metastasis Rev"},{"key":"2025081803480053200_bib37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","article-title":"The development of androgen-independent prostate cancer","volume":"1","author":"Feldman","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"2025081803480053200_bib38","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"2025081803480053200_bib39","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1200\/JCO.2023.41.16_suppl.5070","article-title":"Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"41","author":"Halabi","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025081803480053200_bib40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025081803480053200_bib41","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.3390\/cancers12103065","article-title":"Circulating tumor cells: from the laboratory to the cancer clinic","volume":"12","author":"Sawabata","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025081803480053200_bib42","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1038\/s41467-021-25917-5","article-title":"Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice","volume":"12","author":"Hamza","year":"2021","journal-title":"Nat Commun"},{"key":"2025081803480053200_bib43","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1158\/1078-0432.CCR-18-0862","article-title":"Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis","volume":"24","author":"Lambros","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025081803480053200_bib44","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0090-4295(01)01191-8","article-title":"Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status","volume":"58","author":"Moreno","year":"2001","journal-title":"Urology"},{"key":"2025081803480053200_bib45","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3892\/ijmm.2017.3125","article-title":"Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase","volume":"40","author":"Yu","year":"2017","journal-title":"Int J Mol Med"},{"key":"2025081803480053200_bib46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13578-022-00941-0","article-title":"Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer","volume":"12","author":"Kallenbach","year":"2022","journal-title":"Cell Biosci"},{"key":"2025081803480053200_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-022-02255-y","article-title":"Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation","volume":"41","author":"Merkens","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2025081803480053200_bib48","first-page":"273","article-title":"Neuroendocrine differentiation of prostate cancer: a review","volume":"2","author":"Parimi","year":"2014","journal-title":"Am J Clin Exp Urol"},{"key":"2025081803480053200_bib49","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00345-022-04248-0","article-title":"Chromogranin A: a useful biomarker in castration-resistant prostate cancer","volume":"41","author":"Ploussard","year":"2023","journal-title":"World J Urol"},{"key":"2025081803480053200_bib50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2025081803480053200_bib51","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.7150\/thno.59677","article-title":"Emerging role of circulating tumor cells in immunotherapy","volume":"11","author":"Rzhevskiy","year":"2021","journal-title":"Theranostics"},{"key":"2025081803480053200_bib52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41392-023-01725-9","article-title":"New insights into the correlations between circulating tumor cells and target organ metastasis","volume":"8","author":"Zhan","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"2025081803480053200_bib53","doi-asserted-by":"crossref","first-page":"734595","DOI":"10.3389\/fgene.2021.734595","article-title":"Circulating tumor cells (CTCs): a unique model of cancer metastases and non-invasive biomarkers of therapeutic response","volume":"12","author":"Liu","year":"2021","journal-title":"Front Genet"},{"key":"2025081803480053200_bib54","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00432-021-03583-w","article-title":"Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga\u2013PSMA uptake in LNCaP cells","volume":"147","author":"Mathy","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025081803480053200_bib55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13550-023-01048-4","article-title":"Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study","volume":"13","author":"Sonni","year":"2023","journal-title":"EJNMMI Res"},{"key":"2025081803480053200_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13550-020-00723-0","article-title":"[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study","volume":"10","author":"Hober\u00fcck","year":"2020","journal-title":"EJNMMI Res"},{"key":"2025081803480053200_bib57","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.3390\/jcm12103362","article-title":"Prognostic significance of chromogranin A expression in the initial and second biopsies in metastatic prostate cancer","volume":"12","author":"Huang","year":"2023","journal-title":"J Clin Med"},{"key":"2025081803480053200_bib58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5662\/wjm.v7.i1.9","article-title":"Chromogranin A as a valid marker in oncology: clinical application or false hopes?","volume":"7","author":"Gkolfinopoulos","year":"2017","journal-title":"World J Methodol"},{"key":"2025081803480053200_bib59","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.3390\/ijms21072401","article-title":"Optimization of rVAR2-based isolation of cancer cells in blood for building a robust assay for clinical detection of circulating tumor cells","volume":"21","author":"Sand","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025081803480053200_bib60","doi-asserted-by":"crossref","first-page":"9816","DOI":"10.3390\/ijms25189816","article-title":"Combining rVAR2 and anti-EpCAM to increase the capture efficiency of non-small-cell lung cancer cell lines in the flow enrichment target capture halbach (FETCH) magnetic separation system","volume":"25","author":"He","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025081803480053200_bib61","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/s41467-018-05793-2","article-title":"The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner","volume":"9","author":"Agerb\u00e6k","year":"2018","journal-title":"Nat Commun"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0158\/3637952\/crc-25-0158.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/8\/1359\/3641783\/crc-25-0158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/8\/1359\/3641783\/crc-25-0158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T07:48:15Z","timestamp":1755503295000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/8\/1359\/764160\/PSA-Secretion-from-Single-Circulating-Tumor-Cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0158","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29929858","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929879","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929846","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929867","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929849","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929873","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929861","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929882","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929870","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929888","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929855","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929843","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929876","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929864","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929885","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29929852","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7986577","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}